Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Lung Cancer Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.
Sonam Puri, Abdul Rafeh Naqash, Andrew Elliott, et al.
The study authors conclude that their analysis represents the largest real-world dataset of human SCLC tumors profiled by whole transcriptomic sequencing. They demonstrate differential expression of immune genes and predictive biomarkers across SCLC subtypes. This may inform therapeutic vulnerabilities for rational and personalized treatment approaches in SCLC.
Signatures of plasticity and immunosuppression in a single-cell atlas of human small cell lung cancer.
Joseph Minhow Chan, Alvaro Quintanal-Villalonga, Vianne Gao, et al.
The study authors conclude that the atlas of SCLC illustrates how canonical subtypes and a novel PLCG2-high recurrent tumor subclone enlist diverse gene programs to create tumor heterogeneity and facilitate metastasis in a profoundly immunosuppressed TME. Their dataset provides further insight into the tumor and immune biology in SCLC at single-cell resolution. According to the authors, this has potential implications for the design of novel targeted therapies and immunotherapeutic approaches
Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Taofeek K. Owonikoko, Stéphane Champiat, Melissa Lynne Johnson, et al.
The study authors conclude that AMG 757- a half-life extended BiTE immuno-oncology therapy, which binds DLL3 on tumor cells and CD3 on T cells, leading to T cell-dependent killing of tumors - has an acceptable safety profile at doses up to 100 mg. There were rapid and durable responses with encouraging anti-tumor activity observed across dose ranges, with ongoing unconfirmed partial response in 5/8 pts (63%) at the highest dose levels. Clinical trial information: NCT03319940
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
David R. Spigel, Corinne Faivre-Finn, Jhanelle Elaine Gray, et al.
The study authors conclude that these updated survival analyses demonstrate robust and sustained overall and durable progression-free survival benefit with the PACIFIC regimen (1–42 days following total prescription radiotherapy dose (typically 60–66 Gy in 30–33 fractions) to receive 12 months’ durvalumab (10 mg/kg IV every 2 weeks). 42.9% of patients randomized to durvalumab remain alive at 5 years and approximately 33% remain both alive and free of disease progression. Clinical trial information: NCT02125461
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Salma K. Jabbour, Ki Hyeong Lee, Nicolaj Frost, et al.
The study authors conclude that pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC with longer follow-up. This is regardless of PD-L1 TPS and tumor histology. Clinical trial information: NCT03631784
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
Helen J. Ross, David E. Kozono, James John Urbanic, et al.
Unfortunately, a minority of patients diagnosed annually with stage III NSCLC can be cured by concurrent chemoradiation. The study authors demonstrate that Atezolizumab prior to and following chemoradiation for stage III unresectable NSCLC is well tolerated. The treatment has encouraging progression-free and overall survival. There were no unexpected safety signals. trial information: NCT03102242
Leyla Bayat, Pingfu Fu, Shufen Cao, et al.
The study authors conclude that in patients with SCLC followed over 2 decades, there was a striking 2-fold higher incidence of SCLC in African American females than in African American males. There were no differences in overall and progression-free survival by sex or race. Several genomic alterations occur in higher frequencies in African American patients. In particular, African American women, have higher mutational frequencies.
Impact of socioeconomic disparities on diagnosis and overall survival in small cell lung cancer: A National Cancer Database analysis.
Logan Roof, Wei Wei, Katherine Tullio, et al.
The study authors conclude that despite improvement in overall survival during the time frame studied, there were significant disparities noted in key demographics. They negatively affect access to healthcare resources, including rural communities, distance to an academic center, income, insurer, and education level. The authors state, that collective effort to impact these disparities will likely lead to improved outcomes for patients with SCLC.
Michelle Jeung-Eun Lee, Eric Chang, Manan Shah, et al.
The power of the genomic study to investigate the etiology of health disparities by analyzing the effect of ancestry on genetic alterations in lung adenocarcinoma is clearly shown. The study authors conclude that their results reveal different mutation loads even among African ancestry patients. They observed that African ancestry is associated with worse overall survival. This suggests the possible influence of germline ancestry in subsequent somatic alterations.
Davina Gale, Katrin Heider, Malcolm Perry, et al.
The study authors conclude that their results support an emerging paradigm shift, by demonstrating that liquid biopsies can reliably detect recurrence of NSCLC at a preclinical stage, many months before clinical progression, thereby offering the opportunity for earlier therapeutic intervention. Clinical trial information: NCT04153526
Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.
David Matthew Kurtz, Jacob J. Chabon, Brian Sworder, et al.
The study authors conclude that personalized ctDNA monitoring via "phased variants" is feasible and improves minimal residual disease detection in localized NSCLC. Phased Variant Enrichment and Detection Sequencing allows clinical studies to test personalized treatment based on minimal residual disease.
Dimitrios Mathios, Jakob Sidenius Johansen, Stephen Cristiano, et al.
The study authors conclude that their findings provide key insights into cfDNA fragmentation in patients with cancer and a new and easily accessible avenue for non-invasive diagnosis and molecular profiling of lung cancer.